Obesity hypoventilation syndrome

From Food & Medicine Encyclopedia

Revision as of 21:32, 18 November 2023 by Kondreddy Naveen (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Obesity Hypoventilation Syndrome (OHS)

Overview

Obesity Hypoventilation Syndrome (OHS), also known as Pickwickian Syndrome, is a respiratory disorder primarily affecting individuals with significant obesity. It is characterized by inadequate ventilation in obese individuals, leading to low oxygen levels (hypoxemia) and elevated carbon dioxide (CO2) levels (hypercapnia) in the blood.

Pathophysiology

Mechanism

OHS results from a combination of factors related to obesity, including mechanical effects on the lungs and chest wall, decreased respiratory drive, and hormonal disturbances. The excess weight on the chest and abdomen hinders the normal expansion of the lungs and diaphragm, leading to hypoventilation.

Association with Sleep Disorders

OHS is closely associated with Obstructive Sleep Apnea (OSA) - a condition where excessive fat deposits around the upper airway cause intermittent obstruction during sleep. However, OHS can occur independently of OSA.

Clinical Features

Symptoms

Complications

  • Pulmonary hypertension
  • Right heart failure (cor pulmonale)
  • Secondary erythrocytosis

Diagnosis

Diagnosis involves a combination of clinical evaluation and tests such as:

  • Polysomnography (sleep study)
  • Arterial blood gas analysis
  • Pulmonary function tests
  • Echocardiogram

Treatment

Lifestyle Changes

  • Weight loss
  • Regular exercise
  • Dietary modifications

Medical Management

  • Continuous Positive Airway Pressure (CPAP) or Bi-level Positive Airway Pressure (BiPAP) therapy
  • Oxygen supplementation
  • Medications to treat associated conditions

References

<references/>

Prognosis

With appropriate treatment, the symptoms and complications of obesity hypoventilation syndrome can be managed effectively. Weight loss, in particular, has been shown to improve both respiratory function and overall health outcomes.

Epidemiology

The prevalence of obesity hypoventilation syndrome is increasing, paralleling the rise in obesity rates worldwide. OHS is more common in individuals with a body mass index (BMI) of 40 or higher and is often seen in conjunction with obstructive sleep apnea.

See also

External links

Summary

Obesity hypoventilation syndrome (OHS) is a condition in which severely overweight people fail to breathe rapidly or deeply enough, resulting in low oxygen levels and high blood carbon dioxide (CO2) levels. The syndrome is often associated with obstructive sleep apnea (OSA), which causes periods of absent or reduced breathing in sleep, resulting in many partial awakenings during the night and sleepiness during the day. The disease puts strain on the heart, which may lead to heart failure and leg swelling.

File:WHO Rod.svg
This article is a medical stub. You can help WikiMD by expanding it!
PubMed
Wikipedia



Ad. Transform your life with W8MD's

GLP-1 weight loss injections special from $29.99

W8MD weight loss doctors team
W8MD weight loss doctors team

W8MD Medical Weight Loss, Sleep and Medspa offers physician-supervised medical weight loss programs: NYC medical weight loss Philadelphia medical weight loss

Affordable GLP-1 Weight Loss Shots

Budget GLP-1 injections NYC (insurance & self-pay options) Popular treatments:

✔ Most insurances accepted for visits ✔ Prior authorization support when eligible

Start your physician weight loss NYC journey today:

📍 NYC: Brooklyn weight loss center 📍 Philadelphia: Philadelphia weight loss center

📞 Call: 718-946-5500 (NYC) | 215-676-2334 (Philadelphia)

Tags: Affordable GLP1 weight loss NYC, Wegovy NYC, Zepbound NYC, Philadelphia medical weight loss

File:Linkedin Shiny Icon.svg File:Facebook Shiny Icon.svg File:YouTube icon (2011-2013).svg

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.